Dr. Christopher Kramer: Tirzepatide And Cardiovascular Health | Ep. 11

In this episode of The GLP-1 Podcast Show, I speak with Dr. Christopher Kramer, Chief of the Cardiovascular Division at the University of Virginia Health, about how GLP-1 and GIP therapies are reshaping the treatment of obesity-related heart failure. We explore cardiac remodeling, adipose tissue reduction, cardiovascular outcomes, and the mechanisms behind improved patient health. Listen now on all major platforms! "Treatment with tirzepatide reduced heart failure events by approximately fifty percent while helping patients feel better and perform daily activities more comfortably." Meet the guest: Dr. Christopher Kramer earned his A.B. from Harvard and his M.D. from UCSF before completing cardiology training at the University of Pennsylvania. He is the George A. Beller, MD/Lantheus Medical Imaging Distinguished Professor of Cardiovascular Medicine and Chief of the Cardiovascular Division at the University of Virginia Health. His research focuses on cardiovascular magnetic resonance imaging and heart disease. Listen to Dr. Christopher Kramer on The GLP-1 Podcast Show, available on all major platforms. What you will learn: (00:00) Highlight (01:40) Introduction (09:16) Heart failure outcomes (17:55) Cardiac adipose reduction (23:01) Ventricular remodeling (27:42) Weight loss benefits (30:18) Future triple agonists (31:36) Final Questions The GLP-1 Podcast Show is trusted and supported by innovative companies like: - Elevate - WiseVAs - ZentrixOS - Zentrix Insights 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: The GLP-1 Podcast Show Instagram: The GLP-1 Podcast Show LinkedIn: The GLP-1 Podcast Show YouTube: The GLP-1 Podcast Show Facebook: The GLP-1 Podcast Show TikTok: The GLP-1 Podcast Show